Journal
PATHOGENS
Volume 10, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/pathogens10030370
Keywords
COVID-19; cardiovascular disease; hemostasis
Categories
Ask authors/readers for more resources
COVID-19, caused by SARS-CoV-2 virus, affects respiratory function and disrupts the coagulation system, leading to clotting and thrombotic events. Inflammation and cytokine storms are major causes of hemostasis disorders, with the use of anticoagulants such as heparin recommended to prevent and treat thrombosis. The relationship between blood platelets and COVID-19, as well as the potential use of antiplatelet drugs in COVID-19 cases, are also areas of focus in research.
Although the precise pathogenesis of coronavirus disease 2019 (COVID-19) currently remains unknown, its complex nature is gradually being revealed. COVID-19 is a disease caused by the SARS-CoV-2 virus and leads to respiratory dysfunction. Studies on hemostatic parameters have showed that COVID-19 significantly affects the disruption of the coagulation system and may contribute to coagulation and thrombotic events. A relevant cause of hemostasis disorders is inflammation and cytokine storms, which cause, for example, endothelial dysfunction in blood vessels. In order to prevent and treat states of hypercoagulability and thrombosis, the administration of anticoagulants, e.g., heparin, is recommended. The present mini-review describes the relationship between hemostasis and COVID-19, and discusses whether this relationship may cast light on the nature of COVID-19. The present short manuscript also examines the relationship between blood platelets and COVID-19. In addition, the paper explores the potential use of antiplatelet drugs in COVID-19 cases. The studies were identified by searching electronic databases, including PubMed and SCOPUS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available